Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!

Multiple myeloma (MM) belongs to a heterogeneous group of disorders characterized by a clonal population of hematopoietic B cells. MM is a plasma cell dyscrasia characterized by destructive lytic bone lesions, a plasma cell infiltrate in the bone marrow, and a monoclonal protein in the serum or urine. MM is a disorder of older adults, with a median age at diagnosis of approximately 65 years. A number of cytogenetic abnormalities in the malignant plasma cell clone have been described. These include deletions of chromosome 13 (in about 55% of patients), chromosome 17 deletions (8% of cases), and translocations involving the immunoglobulin heavy chain (IGH). Evolution of myeloma patients is highly variable, with survival ranging from a few months to several years.

13q14, RB1 1p / 1q 4;14 - IGH/FGFR3 17p13 - P53